News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

KaloBios Pharmaceuticals, Inc. Completes $4 Million In Seed Funding From Sofinnova Ventures And Alloy Ventures


10/19/2005 5:11:35 PM

KaloBios, a therapeutic antibody company and developer of proprietary platforms for the discovery of therapeutic proteins and antibodies, announced today the closing of a seed investment round of $4 million. Sofinnova Ventures and Alloy Ventures participated in the financing. Jim Healy, M.D., Ph.D., Managing Director of Sofinnova Ventures, and Doug Kelly, M.D., General Partner of Alloy Ventures, serve on KaloBios’ board.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES